FDA Sticks To Its Guns On Biosimilar Naming

 
• By Dave Wallace
  
Crowd
US Has Doubled Down On Biosimilar Naming Conventions That Set It Apart From The Crowd • Source: Shutterstock

More from Market Intelligence

More from In Vivo